Identification of clinical response predictors of tocilizumab treatment in patients with severe covid-19 based on single-center experience

HIGHLIGHTS

• who: Wiktor Schmidt and colleagues from the Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, JStrus Municipal Hospital, Poznan, Poland Department of Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland have published the Article: Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience, in the Journal: (JOURNAL) of 16/03/2020
• what: The authors aimed to identify good clinical response predictors of tocilizumab (TCZ) treatment in severe COVID-19 among clinical laboratory and radiological variables. The study was developed and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.